{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-063352","form_type":"8-K","ticker":"RNLXY","cik":"0001811115","company_name":"Renalytix plc","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.590922+00:00","generated_at":"2026-06-08T03:56:09.325248+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Renalytix Q1 FY2024 revenue drops 50% YoY to $0.5M; net loss $10.2M; cost cuts underway","bullets":["Revenue $0.5M, down 50% from $1.0M in Q1 FY2023; net loss $10.2M vs $12.0M.","Cost cutting to reduce payroll >35% and total SG&A >30% YoY; cash $13.9M.","Testing volumes 1,297 (56% billable); CMS recommended $950/test for kidneyintelX.dkd, decision Dec 2023.","Howard Doran appointed chief business officer; financing discussions for runway through early 2026.","Expanded commercial payor coverage: BlueCross BlueShield Texas (7M members), Parkland, PNOA."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-063352","json":"https://secwatch.observer/filing/0000950170-23-063352.json","markdown":"https://secwatch.observer/filing/0000950170-23-063352.md","text":"https://secwatch.observer/filing/0000950170-23-063352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811115/000095017023063352/0000950170-23-063352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811115/000095017023063352/rnlx-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:56:09.325248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ec3157c2da92128b6008c5d9bae36d83f601e3b","claim":"Renalytix plc reported first quarter ended September 30, 2023 results: revenue $0.5 million, net income Net loss was $10.2 million.","evidence_excerpt":"During the three months ended September 30, 2023, the Company recognized $0.5 million of revenue, compared to $1.0 million for the three months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017023063352/0000950170-23-063352-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended September 30, 2023"},{"label":"Revenue","value":"$0.5 million"},{"label":"Net income","value":"Net loss was $10.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}